Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | REN | P00797 | 5/20 | 0.40 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16569135 | 1.00 | LMNA (0.45) | LMNAHPGDALDH1A1CYP3A4ALOX15 | |
| SCHEMBL31003034 | 0.79 | PSMB5 (0.48) | ALDH1A1PSMB5SMN1; SMN2RENPSMB8 | |
| SCHEMBL5860469 | 0.78 | ADAMTS4 (0.51) | LMNAHPGDALDH1A1CYP3A4ALOX15 | |
| SCHEMBL5860476 | 0.78 | ADAMTS4 (0.51) | LMNAHPGDALDH1A1CYP3A4ALOX15 | |
| SCHEMBL29885722 | 0.78 | CACNA2D1 (0.42) | ALDH1A1TDP1 | |
| SCHEMBL31633387 | 0.78 | METAP2 (0.41) | PSMB5RENPSMB8 | |
| SCHEMBL2695428 | 0.76 | CACNA2D1 (0.44) | ALDH1A1PSMB5TDP1 | |
| SCHEMBL30442889 | 0.76 | CACNA2D1 (0.44) | ALDH1A1TDP1 | |
| SCHEMBL31515453 | 0.75 | PEPD (0.38) | LMNAHPGDALDH1A1CYP3A4TSHR | |
| SCHEMBL9193585 | 0.75 | LMNA (0.38) | LMNAALDH1A1HIF1AREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514408-B1 | β-secretase enzyme compositions and methods | ELAN PHARMACEUTICALS, INC. (US) | 2009-04-07 | — | — | US | claimed |
| US-20060128963-A1 | Piperidine derivatives as melanocortin-4 receptor agonists | MERCK SHARP & DOHME CORP. | 2006-06-15 | — | — | US | claimed |
| EP-1648457-A2 | PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | Merck & Co., Inc. (US) | 2006-04-26 | — | — | EP | claimed |
| WO-2005009950-A2 | PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2005-02-03 | — | — | WO | claimed |
| US-6833471-B2 | Contacting beta-ketodiester having ketone and two esters with a ketoreductase under conditions permitting reduction of ketone to alcohol, regioselectively hydrolyzing one of ester groups to acid, converting acid or ester to amine | BIOCATALYTICS, INC. | 2004-12-21 | — | — | US | claimed |
| US-20040053377-A1 | Methods for producing hydroxy amino acids and derivatives thereof | CODEXIS, INC. | 2004-03-18 | — | — | US | claimed |
| US-20260125418-A1 | A COMPOUND AND ITS USE FOR DETECTING A DISEASE IN THE EXHALED BREATH OF A SUBJECT | OWLSTONE MED LTD (GB) | 2026-05-07 | — | — | US | disclosed |
| EP-4618952-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | Rhythm Pharmaceuticals, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-4598592-A1 | A COMPOUND AND ITS USE FOR DETECTING A DISEASE IN THE EXHALED BREATH OF A SUBJECT | Owlstone Medical Limited (GB) | 2025-08-13 | — | — | EP | disclosed |
| CN-119585256-A | Chemokine receptor modulators and uses thereof | 拉普特医疗公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-119365493-A | Anti-CD 84 antibodies and uses thereof | 希望之城公司 | 2025-01-24 | — | — | CN | disclosed |
| US-20240325561-A1 | PEGYLATED DRUG-LINKERS FOR IMPROVED LIGAND-DRUG CONJUGATE PHARMACOKINETICS | SEAGEN INC (US) | 2024-10-03 | — | — | US | disclosed |
| WO-2024108198-A2 | METHODS OF TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-6833471-B2 | Contacting beta-ketodiester having ketone and two esters with a ketoreductase under conditions permitting reduction of ketone to alcohol, regioselectively hydrolyzing one of ester groups to acid, converting acid or ester to amine | BIOCATALYTICS, INC. | 2004-12-21 | — | — | US | disclosed |
| US-6833471-B2 | Contacting beta-ketodiester having ketone and two esters with a ketoreductase under conditions permitting reduction of ketone to alcohol, regioselectively hydrolyzing one of ester groups to acid, converting acid or ester to amine | BIOCATALYTICS, INC. | 2004-12-21 | — | — | US | disclosed |
| US-20040053377-A1 | Methods for producing hydroxy amino acids and derivatives thereof | CODEXIS, INC. | 2004-03-18 | — | — | US | disclosed |
| US-20040053377-A1 | Methods for producing hydroxy amino acids and derivatives thereof | CODEXIS, INC. | 2004-03-18 | — | — | US | disclosed |
| EP-0912600-A2 | PEPTIDOMIMETIC INHIBITORS OF CATHEPSIN D AND PLASMEPSINS I AND II | THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-05-06 | — | — | EP | disclosed |
| US-5849691-A | Peptidomimetic inhibitors of cathepsin D and plasmepsins I and II | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-12-15 | — | — | US | disclosed |
| WO-1997030072-A1 | PEPTIDOMIMETIC INHIBITORS OF CATHEPSIN D AND PLASMEPSINS I AND II | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053377-A1 | Methods for producing hydroxy amino acids and derivatives thereof | HMGCR, HSD17B12, BCKDK | LMNA 3159/4885HPGD 61/4885ALDH1A1 514/4885 |
| US-20260125418-A1 | A COMPOUND AND ITS USE FOR DETECTING A DISEASE IN THE EXHALED BREATH OF A SUBJECT | BRCA1, L3MBTL1, LMNA | LMNA 3/4885HPGD 1055/4885ALDH1A1 1039/4885 |
| US-20060128963-A1 | Piperidine derivatives as melanocortin-4 receptor agonists | MC4R, MC5R, MC1R | LMNA 4631/4885HPGD 2186/4885ALDH1A1 2981/4885 |
| US-20240325561-A1 | PEGYLATED DRUG-LINKERS FOR IMPROVED LIGAND-DRUG CONJUGATE PHARMACOKINETICS | EGFR, HDGF, CD47 | LMNA 155/4885HPGD 1979/4885ALDH1A1 1001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.